JPRN-UMIN000018445招募中未知
Efficacy and safety of DPP-4 inhibitors in diabetic patients undergoing hemodialysis - DPP-4 inhibitors in diabetic patients on HD
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Infectious disease, 2) Thyroid disease, 3) Malignant tumors, 4) Liver dysfunction, 5) Type 1 diabetes, 6)Treatment with steroids or immunosuppressant, 7) History of severe heart failure, angina, myocardial infarction, or stroke within the past 6 months, 8) Currently hospitalization.
研究者
相似试验
进行中（未招募）
不适用
ANTIDIABETIC EFFECTS OF ADDING A DPP-4 INHIBITOR (SITAGLIPTIN) TO PRE-EXISTING TREATMENT WITH AN INCRETIN MIMETIC (LIRAGLUTIDE) IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH METFORMITYPE 2 DIABETESMedDRA version: 16.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-001764-35-DEDiabeteszentrum Bad Lauterberg
进行中（未招募）
1 期
DPP4inhibitors in Type 1 DiabetesType 1 DiabetesEUCTR2012-002407-18-GBniversity of Dundee and NHS Tayside12
已完成
不适用
The efficacy of DPP-4 inhibitors and alpha glucosidase inhibitors for type 2diabetesPatients with type 2 diabetesJPRN-UMIN000011788ational Center for Global Health and Medicine15
已完成
不适用
Efficacy and safety of DPP-4 inhibitors in patients with chronic kidney diseaseJPRN-UMIN000018464ihon University School of Medicine100
招募中
不适用
Efficacy and safety of DPP-4 inhibitors in patients with chronic kidney diseaseChronic kidney diseaseJPRN-UMIN000009493ihon University School of Medicine30